Serum 25-hydroxyvitamin D concentrations in 16-year-old Icelandic adolescent and its association with bone mineral density by Gudmundsdottir, Sigridur Lara et al.
Short Communication
Serum 25-hydroxyvitamin D concentrations in 16-year-old
Icelandic adolescent and its association with bone
mineral density
SL Gudmundsdottir1,*, H Hrafnkelsson2,3, EL Sigurdsson2,3 and E Johannsson1,4
1Center for Sport and Health Science, School of Education, University of Iceland, Reykjavik, Iceland: 2Development
Centre for Primary Health Care in Iceland, Hafnarfjordur, Iceland: 3Department of Family Medicine, University of
Iceland, Reykjavik, Iceland: 4Department of Sport and Physical Activity, Western Norway University of Applied
Sciences, Bergen, Norway
Submitted 12 March 2019: Final revision received 13 September 2019: Accepted 23 September 2019: First published online 19 March 2020
Abstract
Objective: The aim of the study was to assess the potential association between
serum 25-hydroxyvitamin D (25(OH)D) and whole-body bone mineral density
(BMD) among 16-year-old adolescents and to study the prevalence of 25(OH)D
insufficiency, defined as concentration under 50 nmol/l.
Design: A cross-sectional study.
Setting: Reykjavik, Iceland, latitude 64°08 0N. Measurements took place in the
Icelandic Heart Association's research lab during April–June 2015.
Participants: In total, 411 students in Reykjavik, Iceland, were invited to participate,
315 accepted the invitation (76·6 %) and 289 had valid data (mainly Caucasian).
Results: 25(OH)D < 50 nmol/l was observed in 70 % of girls and 66·7 % of boys.
25(OH)D ≥ 50 nmol/l was significantly associated with higher whole-body BMD
after adjusting for the influence of sex, height, fat mass and lean mass. A linear
relationship between 25(OH)D and whole-body BMD was significant for 25(OH)
D < 50 nmol/l (n 199, P < 0·05) but NS for 25(OH)D ≥ 50 nmol/l
(n 86, P = 0·48).
Conclusions:Our results are in line with some but not all previous studies on the rela-
tionship between BMD and 25(OH)D in adolescents. The observed difference in
BMD between those with above v. below a 25(OH)D concentration of 50 nmol/l
was of about a fifth of one SD,whichmayhavea clinical relevance as one SDdecrease
in volumetric BMDhas been associatedwith a 89 % increase in 2 years risk of fracture.
Icelandic adolescents should be encouraged to increase their vitamin D intake as it is







Vitamin D affects bone remodelling and is necessary for
healthy bone tissue. Recommended serum concentrations
of 25-hydroxyvitamin D (25(OH)D) for adults and healthy
children to maintain good bone health and decrease risk of
fractures in old age are 40–50 nmol/l(1,2). Rickets was eradi-
cated in Europe with discoveries of the positive effects of
sunlight and vitamin D in the 19th and 20th centuries(3).
Low 25(OH)D concentrations are of concern in many
countries(4) as research indicates that worldwide, less than
half of the population has sufficient 25(OH)D, at least
during winter(5). In studies of Icelandic children born in
1999, our research group reported that at the age of 7 and
9, 65 % and 66 %, respectively, had 25(OH)D concentra-
tion under 50 nmol/l(6,7) but in another cohort of 6-year-
old children born in 2005, this proportion was 36 %(8).
About one-third of peak bone mass is formed during the
years of sexual maturation and peak growth velocity(9,10).
Low peak bone mass is thought to be associated with risk
of osteoporosis and fractures later in life(11). The association
between 25(OH)D and bone mineral density (BMD)
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among adolescents is uncertain, and study results are
inconsistent. A recent Australian study suggests an associ-
ation between the trajectories of 25(OH)D from childhood
to early adulthood and bone mass at age 20 among males
but not females(12). On the other hand, a US study found
lower BMD among teenage girls with low 25(OH)D, but the
association was not observed among boys(13). A Finnish
study that included girls only found that 25(OH)Ddeficiency
was associated with significantly lower BMD measured in
the distal radius and tibia shaft(14). Conversely, a previous
Icelandic study did not find an association between
25(OH)D and BMD among 16–20-year-old females(15).
Considering the northern latitude of Reykjavik, Iceland
(64°08 0N), the 25(OH)D concentration is likely to be low in
the inhabitants, at least during winter. Whether this has any
relationship with low BMD, and in particular the high inci-
dence of fractures in the Nordic countries has not been
excluded. Our previous study indicates that although more
than 60 % of the children in the 1999 birth year cohort had
inadequate 25(OH)D concentration at ages 7 and 9, no
associationwas observedwith BMDor bone accrual during
a 2-year follow-up(16). In 2015, a health study of the 1999
birth year cohort was performed, including many of the
participants from our former studies, as well as additional
subjects. It was therefore of interest to investigate the
association between 25(OH)D and BMD following sexual
maturation and peak growth velocity. Serum 25(OH)
D < 50 nmol/l is globally accepted as insufficient vitamin
D status(17). Hence, the main aim of the current study
was to assess the potential cross-sectional association
between serum 25(OH)D and whole-body BMD among
16-year-old adolescents and to study 25(OH)D concentra-
tion in this same cohort, with the aim of study the preva-
lence of 25(OH)D insufficiency, defined as <50 nmol/l,
in line with other Nordic and European countries(18,19).
Methods
This is a cross-sectional study based on data collected dur-
ing April–June 2015. Students in 10th grade in the same six
schools as were included in a previous study(16) were
invited to participate. Some of the previous participants
had moved and new students enrolled since the last data
collection at the age of 9. Thus, this study includes many
of the participants from the former study with additional
students invited to the current one. A total of 411 students
were invited by letter to participate and 315 accepted the
invitation (76·6 % participation rate). Measurements took
place in the Icelandic Heart Association's research lab in
Kopavogur. This study was conducted according to the
guidelines laid down in the Declaration of Helsinki, and
all procedures involving research study participants were
approved by The National Bioethics Committee. Written
informed consent was obtained from all adolescents and
their guardians before participation.
Bodyweight (kg) wasmeasured to the nearest 0·1 kg on
a calibrated scale (Seca model 813; Seca Ltd.), with partici-
pants wearing light clothing and standing height (m) to the
nearest mmwith a stadiometer (Seca model 217; Seca Ltd.).
BMI was determined by dividing weight by height squared
(kg/m2). Participants were classified as normal, overweight
or obese as suggested by Cole et al.(20).
Fasting venous blood samples were collected with a
Vacutainer® System (Becton Dickinson). Samples were
centrifuged within 30 min and stored at −80°C until analy-
sis when it was thawed at room temperature (only thawed
once). The measure of the quantitative determination of
total 25(OH)D (nmol/l) was made on Cobas e 411 (Roche)
using the vitamin D total assay from Roche, a competitive
electrochemiluminescence-binding assay. Calibration was
done with the vitamin D total Calset (standard). The inter-
assay CV was <6·34 % when calculated data are from mea-
surements using a frozen serum pool as the control sample
and <12·80 % when calculated data are from measurements
using Roche quality controls.
Intact parathyroid hormone (PTH) (ng/l) in serum was
measured using the PTH-intact assay from Roche, a sand-
wich electrochemiluminescence immunoassay ‘ECLIA’ on
Cobas e 411 (Roche, Switzerland). The inter-assay CV
was 6·0 % using a frozen serum pool and <4·8 % using
quality control samples from Roche.
Whole-body bone mineral density and bone mineral
content (BMC), fat and lean tissue composition was mea-
sured by dual-energy X-ray absorptiometry (DXA) with
Lunar bone densitometer (Lunar iDXA, General Electric
Healthcare). Due to financial constraints, regional sites
were not assessed. All DXA-scans were run by a single cer-
tified radiologist. Daily quality assessment included a scan
of the standard calibration image quality assurance (IQA)
phantom (Lunar iDXA) that includes different densities
(Lunar iDXA). The daily phantom scans demonstrated very
stable scanner over the course of the study period with an
average CV of 0·19 % for BMD.
Descriptive summaries are presented as means and SDs
for continuous variables. Differences between the sexes
were evaluated by unpaired t-tests. The association
between serum 25(OH)D and PTH was assessed with
Pearson's correlation coefficient. Linear regression model
was performed with whole-body BMD as the dependent
factor and 25(OH)D as independent factor. Based primarily
on a priori considerations, sex, height, fat mass and lean
body mass were considered as covariates(21). Collinearity
between lean and fat mass was assessed and found non-
significant. There was however a significant correlation
between 25(OH)D and PTH, and hence, PTH was not
included in the model. Thus, we could evaluate the
association between 25(OH)D andwhole-body BMD inde-
pendent of potential confounding factors. Regression
analyses were performed for the total group to preserve
statistical power instead of for each sex specifically. In
the linear regression, subjects were classified according
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to their 25(OH)D concentration, <50 v. ≥50 nmol/l in
accordance with guidelines from i.a. the Icelandic
Directorate of Health(1) and to enable comparison with pre-
vious studies of the Icelandic paediatric population(6,7,16).
An additional analysis treating 25(OH)D as a continuous
variable was run to confirm the former. To investigate if
a 25(OH)D concentration of <50 nmol/l is indeed a mean-
ingful threshold value, we stratified the sample by this
value and investigated the linear relationship between
25(OH)D and whole-body BMD adjusting for the afore-
mentioned parameters. This was repeated for 25(OH)
D < 37·5 nmol/l. Significant differences or relations were
accepted at α < 0·05. Statistical analyses were performed
using the statistical software package IBM SPSS statistics,
version 24 (IBM Corporation).
Results
Out of the 315 adolescents participating in the study,
307 had DXA measurements and 293 had valid 25(OH)D
measures, 289 had valid measures on all parameters
included in the analyses. Subject characteristics are shown
in Table 1. 25(OH)D < 50 nmol/l was observed in 70 % of
girls and 66·7 % of boys.
The adjusted associations observed between the lower
v. higher category of 25(OH)D and whole-body BMD are
shown in Table 2. 25(OH)D equal to or above 50 nmol/l
was significantly associated with higher whole-body
BMD after adjusting for the influence of sex, height, fat
mass and lean mass. Of the covariates included in the
model, all but fat mass were significantly associated with
whole-body BMD. Comparable results were found when
25(OH)D was treated as a continuous variable, a positive
association was observed with increasing 25(OH)D
values and higher whole-body BMD (P = 0·01, data not
shown). When stratifying the sample by 25(OH)D status, we
found a significant adjusted relationship between 25(OH)
D < 50 nmol/l (n 199, P < 0·05) and whole-body BMD,
while the association was NS for those with 25(OH)
D > 50 nmol/l (n 86, P = 0·48). The association was similar
when the threshold concentration was set to <37·5 nmol/l
(n 143, P < 0·05).
There was also a significant association between higher
BMC and increasing 25(OH)D concentration when adjust-
ing for sex, height, fat mass, lean body mass and bone area
(P = 0·03). No significant association was found between
25(OH)D and bone area. There was a significant negative
correlation between 25(OH)D and PTH (r = −0·39,
P < 0·01).
Discussion
In the current study, we aimed to study the concentration of
serum 25(OH)D and its association with whole-body BMD
in a cohort of 16-year-old Icelandic adolescents after adjust-
ing for sex, height, fat and lean mass. We found that 70 %
of girls and 66·7 % of boys had 25(OH)D < 50 nmol/l, a
higher proportion than previously reported for younger
Icelandic children(6,7) but similar to Norwegian adolescents,
where 60·2 % had 25(OH)D < 50 nmol/l(18). Adolescents
Table 1 Characteristics of study participants
Females (n 183) Males (n 132) Difference between the sexes
Mean SD Mean SD P value
Age 15·9 0·3 15·8 0·3 0·09
Height (cm) 166·8 5·7 178·2 5·7 <0·001
Weight (kg) 61·7 10·1 69·0 11·3 <0·001
BMI (kg/m2) 22·2 3·2 21·7 3·3 0·240
Normal weight (%) 79·1 81·3 <0·05
Overweight (%) 17·6 14·0
Obesity (%) 3·3 4·7
Fat mass (kg) 19·0 6·7 13·4 7·8 <0·001
Fat (%) 31·3 6·2 19·3 7·7 <0·001
Lean body mass (kg) 40·4 4·8 53·0 6·3 <0·001
Bone mass (kg) 2·3 0·3 2·8 0·4 <0·001
Bone mineral density (g/cm2) 1·101 0·089 1·138 0·107 0·001
PTH (ng/l) 39·4 13·3 42·2 14·1 0·08
25(OH)D (nmol/l) 43·1 23·0 42·0 22·7 0·67
25(OH)D < 50 nmol/l n (%) 70 66·7 0·54
Table 2 Linear regression relationship between 25(OH)D nmol/l
and whole-body bone mineral density (g/cm2)
B β SE P
25(OH)D ≥ 50 nmol/l 0·023 0·109 0·009 0·009
Sex (male) 0·124 0·015 0·623 <0·001
Height (cm) −0·002 −0·174 0·001 0·015
Fat mass (kg) −0·001 −0·050 0·001 0·293
Lean mass (kg) 0·014 1·197 0·001 <0·001
R2 = 0·534
B, unstandardised regression coefficient; β, standardised coefficient.
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with serum 25(OH)D < 50 nmol/l had significantly lower
BMD than those above this threshold value, in agree-
ment with some(12) but not all(13,14) earlier studies on this
relationship.
The current findings indicate that the concentration of
25(OH)D in Icelandic children and adolescents decreases
with increasing age with 92 % of infants having 25(OH)D
above 50 nmol/l(22), 35 % of subjects at the age of 7 and
40 % at the age of 9(16). Similar age-related patterns have
been reported among Norwegian children and adoles-
cents(23). At the age of 7 and 9, we did not find an associ-
ation between bone parameters and 25(OH)D and at those
ages the association between PTH and 25(OH)D was weak
but significant at age 7 (r = –0·21, P < 0·05) but insignifi-
cant at age 9 (r = –0·11, P = 0·18)(16). In the current
study, the strength of the association has increased to –0·39.
This is in agreement with prior studies in adolescents,
although it is important to note that the association
between 25(OH)D, PTH and bone health in this age group
is not fully understood(24).
Our results are in line with some(12) but not all(13,14) pre-
vious studies on the relationship between BMD and
25(OH)D in adolescents. For example, a prior Icelandic
study did not find an association between 25(OH)D and
BMD among 16–20-year-old females(15), although it
should be noted that height and lean body mass were
not adjusted for as confounding factors, as has been
suggested(25,26). In a study among Chinese children and
adolescents aged 6–18 years, no association was observed
between serum 25(OH)D concentrations and whole-body
BMD, but the authors suggest that a dietary enhancement
or vitamin D supplementation should be considered for
those children who have developed low BMD, to ensure
that they can achieve optimal peak bone mass(27).
The observed difference in BMD between those with
above v. below a 25(OH)D concentration of 50 nmol/l
was of about a fifth of one SD, which may have a clinical
relevance. In children and adolescents, lower BMD corre-
lates with increased fracture risk during the years of bone
accrual, where one SD decrease in volumetric BMD has
been associated with a 89 % increase in two years risk of
fracture(28). The subjects in the current study are probably
in the final stages of a period of peak bone accretion(29),
and although the variance of peak bone mass is largely
genetically determined, environmental and modifiable
factors, such as adequate intake of 25(OH)D, are also
important(30) as maximising peak bonemass may contribute
to higher BMD later in life and possibly prevent osteoporotic
fractures(31).
The main strength of the present study is that all partici-
pants came from a single birth year cohort. Many of the
participants have previously participated in studies of the
association between vitamin D status and bone health(16),
allowing us to have insight into the trend of this association
within the 1999 cohort. The main limitation of the study is
its cross-sectional design. Therefore, no conclusion can be
made regarding the causality of the association between
the parameters under study. Unfortunately, information
regarding nutrition or vitamin D supplementation was
not available, as this would have strengthened the study.
Furthermore,we only hadwhole-bodyBMDbut not specific
sites that are of particular interest for bone health in adoles-
cents, such as total body less head or the lumbar spine(32).
The northern latitude and homogeneous Caucasian
composition of the Icelandic population may further limit
the generalisability of the findings.
Our results indicate a high prevalence of 25(OH)D
insufficiency among Icelandic youth, with lower bone min-
eral density values observed in those with low 25(OH)D.
We conclude that it is important for Icelandic adolescents
to increase their vitamin D intake as it is possible that their
current intake is insufficient to achieve optimal peak
bone mass.
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